8-K current report · filed Nov 9, 2026

Septerna, Inc. (SEPN) 8-K Current Report: November 9, 2026

Item 2.02Item EX-99.1SEPN overview

Short answer

Septerna, Inc. (SEPN) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results and business highlights announced for the quarter ended September 30, 2026.

Septerna, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 results and business highlights announced for the quarter ended September 30, 2026
  • Detailed financial figures and operating updates available in Exhibit 99.1 press release
  • Investor focus: cash position, pipeline progress and development spending in the accompanying release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 2026 revenue $18.9M, including $5.2M milestone revenue and $11.0M Novo research services
  • Net loss $26.6M versus $8.2M net income, reflecting higher R&D expense of $36.6M
  • Cash, equivalents and marketable securities $565.2M, supporting operations at least into mid-2029
  • SEP-479 Phase 1 SAD/MAD data expected Q1 2027, the next key clinical catalyst
  • SEP-204 Phase 1 trial planned for Q1 2027, expanding the pipeline into Graves’ disease and thyroid eye disease

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Septerna, Inc. 8-K filings

Get the next SEPN 8-K as it lands

Follow SEPN for push alerts, or ask the research agent what this filing means.